Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy
Psoriatic spondyloarthropathy (PSA) can occasionally be complicated by AA amyloid, and renal amyloidosis should be suspected in patients with PSA who have unexplained proteinuria. The diagnosis of amyloidosis can be made either histologically or by radiolabelled serum amyloid P component (SAP) scint...
Gespeichert in:
Veröffentlicht in: | British journal of rheumatology 2003-02, Vol.42 (2), p.362-366 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 366 |
---|---|
container_issue | 2 |
container_start_page | 362 |
container_title | British journal of rheumatology |
container_volume | 42 |
creator | Mpofu, S. Teh, L. S. Smith, P. J. Moots, R. J. Hawkins, P. N. |
description | Psoriatic spondyloarthropathy (PSA) can occasionally be complicated by AA amyloid, and renal amyloidosis should be suspected in patients with PSA who have unexplained proteinuria. The diagnosis of amyloidosis can be made either histologically or by radiolabelled serum amyloid P component (SAP) scintigraphy. Prognosis is determined by the extent of organ involvement and associated impairment of function, and by the degree of response of the underlying disease to anti‐inflammatory therapy. A review of the literature identified less than a dozen cases of AA amyloidosis complicating PSA, and the outcome in most cases was poor. We report here the favourable clinical course of a middle‐aged Caucasian male patient with severe PSA who developed renal AA amyloidosis, in whom treatment with oral chlorambucil led to stabilization of the amyloid deposits and resolution of the associated nephrotic syndrome. We review the diagnosis and treatment of AA amyloidosis, including the management of patients with underlying inflammatory spondyloarthropathies, and propose the possible role of a therapeutic trial of anti‐tumour necrosis factor α in patients with amyloid complicating inflammatory rheumatic diseases. |
doi_str_mv | 10.1093/rheumatology/keg101 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73025194</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73025194</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-3d894a0f61e91c783a20dc08464551d999ecdcbdc66ac40912446075a1a1bc5d3</originalsourceid><addsrcrecordid>eNpd0F1rFDEUBuAgiv3QXyDIINi7scnka3K5LNoKC1ZREW_C2SSzm3ZmMk0y4Px7o7u04lUO5HkPhxehVwS_I1jRy7h38wA59GG3XN65HcHkCTolTDQ1prR5-jA37ASdpXSLMeaEts_RCWm44oLKU3SzXnJIGbI3Vd67CNNSdSFWq1UFw9IHb0PyqTJhmHpvCht31ZRC9H8TaQqjLQpi3scwQd4vL9CzDvrkXh7fc_Ttw_uv6-t68-nq43q1qQ1jJNfUtooB7gRxihjZUmiwNbhlgnFOrFLKGWu21ggBhmFFGsYElhwIkK3hlp6ji8PeKYb72aWsB5-M63sYXZiTlhQ3nChW4Jv_4G2Y41hu06SUwKVoaUH0gEwMKUXX6Sn6AeKiCdZ_2tb_tq0PbZfU6-PqeTs4-5g51lvA2yOAZKDvIozGp0fHOJVS8uLqg_Mpu18P_xDvtJBUcn3946f-rr7ctFebz3pNfwMLS50j</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>195657683</pqid></control><display><type>article</type><title>Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Mpofu, S. ; Teh, L. S. ; Smith, P. J. ; Moots, R. J. ; Hawkins, P. N.</creator><creatorcontrib>Mpofu, S. ; Teh, L. S. ; Smith, P. J. ; Moots, R. J. ; Hawkins, P. N.</creatorcontrib><description>Psoriatic spondyloarthropathy (PSA) can occasionally be complicated by AA amyloid, and renal amyloidosis should be suspected in patients with PSA who have unexplained proteinuria. The diagnosis of amyloidosis can be made either histologically or by radiolabelled serum amyloid P component (SAP) scintigraphy. Prognosis is determined by the extent of organ involvement and associated impairment of function, and by the degree of response of the underlying disease to anti‐inflammatory therapy. A review of the literature identified less than a dozen cases of AA amyloidosis complicating PSA, and the outcome in most cases was poor. We report here the favourable clinical course of a middle‐aged Caucasian male patient with severe PSA who developed renal AA amyloidosis, in whom treatment with oral chlorambucil led to stabilization of the amyloid deposits and resolution of the associated nephrotic syndrome. We review the diagnosis and treatment of AA amyloidosis, including the management of patients with underlying inflammatory spondyloarthropathies, and propose the possible role of a therapeutic trial of anti‐tumour necrosis factor α in patients with amyloid complicating inflammatory rheumatic diseases.</description><identifier>ISSN: 1462-0324</identifier><identifier>ISSN: 1460-2172</identifier><identifier>EISSN: 1462-0332</identifier><identifier>EISSN: 1460-2172</identifier><identifier>DOI: 10.1093/rheumatology/keg101</identifier><identifier>PMID: 12595637</identifier><identifier>CODEN: BJRHDF</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>AA amyloidosis ; Amyloidosis - drug therapy ; Amyloidosis - etiology ; Anti‐TNF ; Arthritis, Psoriatic - complications ; Biological and medical sciences ; Chlorambucil ; Chlorambucil - therapeutic use ; Dermatology ; Follow-Up Studies ; Humans ; Kidney Diseases - drug therapy ; Kidney Diseases - etiology ; Male ; Medical sciences ; Middle Aged ; Psoriasis. Parapsoriasis. Lichen ; Psoriatic spondyloarthropathy ; Serum Amyloid A Protein - analysis ; Spondylarthropathies - complications</subject><ispartof>British journal of rheumatology, 2003-02, Vol.42 (2), p.362-366</ispartof><rights>2003 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Feb 2003</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-3d894a0f61e91c783a20dc08464551d999ecdcbdc66ac40912446075a1a1bc5d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14537775$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12595637$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mpofu, S.</creatorcontrib><creatorcontrib>Teh, L. S.</creatorcontrib><creatorcontrib>Smith, P. J.</creatorcontrib><creatorcontrib>Moots, R. J.</creatorcontrib><creatorcontrib>Hawkins, P. N.</creatorcontrib><title>Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy</title><title>British journal of rheumatology</title><addtitle>Rheumatology</addtitle><description>Psoriatic spondyloarthropathy (PSA) can occasionally be complicated by AA amyloid, and renal amyloidosis should be suspected in patients with PSA who have unexplained proteinuria. The diagnosis of amyloidosis can be made either histologically or by radiolabelled serum amyloid P component (SAP) scintigraphy. Prognosis is determined by the extent of organ involvement and associated impairment of function, and by the degree of response of the underlying disease to anti‐inflammatory therapy. A review of the literature identified less than a dozen cases of AA amyloidosis complicating PSA, and the outcome in most cases was poor. We report here the favourable clinical course of a middle‐aged Caucasian male patient with severe PSA who developed renal AA amyloidosis, in whom treatment with oral chlorambucil led to stabilization of the amyloid deposits and resolution of the associated nephrotic syndrome. We review the diagnosis and treatment of AA amyloidosis, including the management of patients with underlying inflammatory spondyloarthropathies, and propose the possible role of a therapeutic trial of anti‐tumour necrosis factor α in patients with amyloid complicating inflammatory rheumatic diseases.</description><subject>AA amyloidosis</subject><subject>Amyloidosis - drug therapy</subject><subject>Amyloidosis - etiology</subject><subject>Anti‐TNF</subject><subject>Arthritis, Psoriatic - complications</subject><subject>Biological and medical sciences</subject><subject>Chlorambucil</subject><subject>Chlorambucil - therapeutic use</subject><subject>Dermatology</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Kidney Diseases - drug therapy</subject><subject>Kidney Diseases - etiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Psoriasis. Parapsoriasis. Lichen</subject><subject>Psoriatic spondyloarthropathy</subject><subject>Serum Amyloid A Protein - analysis</subject><subject>Spondylarthropathies - complications</subject><issn>1462-0324</issn><issn>1460-2172</issn><issn>1462-0332</issn><issn>1460-2172</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpd0F1rFDEUBuAgiv3QXyDIINi7scnka3K5LNoKC1ZREW_C2SSzm3ZmMk0y4Px7o7u04lUO5HkPhxehVwS_I1jRy7h38wA59GG3XN65HcHkCTolTDQ1prR5-jA37ASdpXSLMeaEts_RCWm44oLKU3SzXnJIGbI3Vd67CNNSdSFWq1UFw9IHb0PyqTJhmHpvCht31ZRC9H8TaQqjLQpi3scwQd4vL9CzDvrkXh7fc_Ttw_uv6-t68-nq43q1qQ1jJNfUtooB7gRxihjZUmiwNbhlgnFOrFLKGWu21ggBhmFFGsYElhwIkK3hlp6ji8PeKYb72aWsB5-M63sYXZiTlhQ3nChW4Jv_4G2Y41hu06SUwKVoaUH0gEwMKUXX6Sn6AeKiCdZ_2tb_tq0PbZfU6-PqeTs4-5g51lvA2yOAZKDvIozGp0fHOJVS8uLqg_Mpu18P_xDvtJBUcn3946f-rr7ctFebz3pNfwMLS50j</recordid><startdate>20030201</startdate><enddate>20030201</enddate><creator>Mpofu, S.</creator><creator>Teh, L. S.</creator><creator>Smith, P. J.</creator><creator>Moots, R. J.</creator><creator>Hawkins, P. N.</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20030201</creationdate><title>Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy</title><author>Mpofu, S. ; Teh, L. S. ; Smith, P. J. ; Moots, R. J. ; Hawkins, P. N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-3d894a0f61e91c783a20dc08464551d999ecdcbdc66ac40912446075a1a1bc5d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>AA amyloidosis</topic><topic>Amyloidosis - drug therapy</topic><topic>Amyloidosis - etiology</topic><topic>Anti‐TNF</topic><topic>Arthritis, Psoriatic - complications</topic><topic>Biological and medical sciences</topic><topic>Chlorambucil</topic><topic>Chlorambucil - therapeutic use</topic><topic>Dermatology</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Kidney Diseases - drug therapy</topic><topic>Kidney Diseases - etiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Psoriasis. Parapsoriasis. Lichen</topic><topic>Psoriatic spondyloarthropathy</topic><topic>Serum Amyloid A Protein - analysis</topic><topic>Spondylarthropathies - complications</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mpofu, S.</creatorcontrib><creatorcontrib>Teh, L. S.</creatorcontrib><creatorcontrib>Smith, P. J.</creatorcontrib><creatorcontrib>Moots, R. J.</creatorcontrib><creatorcontrib>Hawkins, P. N.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mpofu, S.</au><au>Teh, L. S.</au><au>Smith, P. J.</au><au>Moots, R. J.</au><au>Hawkins, P. N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy</atitle><jtitle>British journal of rheumatology</jtitle><addtitle>Rheumatology</addtitle><date>2003-02-01</date><risdate>2003</risdate><volume>42</volume><issue>2</issue><spage>362</spage><epage>366</epage><pages>362-366</pages><issn>1462-0324</issn><issn>1460-2172</issn><eissn>1462-0332</eissn><eissn>1460-2172</eissn><coden>BJRHDF</coden><abstract>Psoriatic spondyloarthropathy (PSA) can occasionally be complicated by AA amyloid, and renal amyloidosis should be suspected in patients with PSA who have unexplained proteinuria. The diagnosis of amyloidosis can be made either histologically or by radiolabelled serum amyloid P component (SAP) scintigraphy. Prognosis is determined by the extent of organ involvement and associated impairment of function, and by the degree of response of the underlying disease to anti‐inflammatory therapy. A review of the literature identified less than a dozen cases of AA amyloidosis complicating PSA, and the outcome in most cases was poor. We report here the favourable clinical course of a middle‐aged Caucasian male patient with severe PSA who developed renal AA amyloidosis, in whom treatment with oral chlorambucil led to stabilization of the amyloid deposits and resolution of the associated nephrotic syndrome. We review the diagnosis and treatment of AA amyloidosis, including the management of patients with underlying inflammatory spondyloarthropathies, and propose the possible role of a therapeutic trial of anti‐tumour necrosis factor α in patients with amyloid complicating inflammatory rheumatic diseases.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>12595637</pmid><doi>10.1093/rheumatology/keg101</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1462-0324 |
ispartof | British journal of rheumatology, 2003-02, Vol.42 (2), p.362-366 |
issn | 1462-0324 1460-2172 1462-0332 1460-2172 |
language | eng |
recordid | cdi_proquest_miscellaneous_73025194 |
source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
subjects | AA amyloidosis Amyloidosis - drug therapy Amyloidosis - etiology Anti‐TNF Arthritis, Psoriatic - complications Biological and medical sciences Chlorambucil Chlorambucil - therapeutic use Dermatology Follow-Up Studies Humans Kidney Diseases - drug therapy Kidney Diseases - etiology Male Medical sciences Middle Aged Psoriasis. Parapsoriasis. Lichen Psoriatic spondyloarthropathy Serum Amyloid A Protein - analysis Spondylarthropathies - complications |
title | Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T09%3A12%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cytostatic%20therapy%20for%20AA%20amyloidosis%20complicating%20psoriatic%20spondyloarthropathy&rft.jtitle=British%20journal%20of%20rheumatology&rft.au=Mpofu,%20S.&rft.date=2003-02-01&rft.volume=42&rft.issue=2&rft.spage=362&rft.epage=366&rft.pages=362-366&rft.issn=1462-0324&rft.eissn=1462-0332&rft.coden=BJRHDF&rft_id=info:doi/10.1093/rheumatology/keg101&rft_dat=%3Cproquest_cross%3E73025194%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=195657683&rft_id=info:pmid/12595637&rfr_iscdi=true |